Can TVTX sustain its earnings momentum into 2025?

**Travere Therapeutics (TVTX) is poised to maintain its earnings momentum into 2025**, based on several key factors: 1. **Expected Earnings Growth**: TVTX is anticipated to deliver a year-over-year increase in earnings, with a consensus EPS estimate for the upcoming quarter being $-0.58, representing a 50% year-over-year change. This indicates a strong earnings growth trajectory. |code|Ticker|Name|Date|Net Income YoY|Total Revenue YoY|Diluted EPS YoY|market_code| |---|---|---|---|---|---|---|---| |TVTX|TVTX.O|Travere Therapeutics|2024 Q1|-57.603873463761566|33.94845894845895|-38.582677165354326|185| |TVTX|TVTX.O|Travere Therapeutics|2024 Q2|17.775312390517342|68.0829916759846|19.469026548672556|185| |TVTX|TVTX.O|Travere Therapeutics|2024 Q3|-136.36249046339603|69.55923978972908|-135.53299492385787|185| |TVTX|TVTX.O|Travere Therapeutics|2024 Q4|33.16846506160381|65.9757207217204||185| 2. **Revenue Growth**: The company's total revenue is expected to be $73.44 million, marking a 63% increase from the previous year's same quarter. This substantial revenue growth is a clear indicator of TVTX's ability to sustain its financial performance. 3. **Analyst Optimism**: Analysts have provided Travere Therapeutics with a consensus rating of "Buy," with an average one-year price target of $22.17, suggesting a potential 20.69% upside. This positive sentiment reflects confidence in TVTX's future earnings potential. 4. **Business Performance**: TVTX's flagship drug, Filspari, has shown significant growth, with a 40% increase in net product sales in Q4 compared to the previous quarter. The company has also received 693 new patient start forms for Filspari in Q4, indicating strong demand and market acceptance. 5. **Corporate Developments**: TVTX is actively pursuing additional indications for Filspari, including FSGS, which could open up new markets and further boost earnings. The company's strategic initiatives, such as the submission of an sNDA to the FDA for FSGS, are expected to contribute to its long-term growth. In conclusion, Travere Therapeutics' strong earnings growth, positive analyst sentiment, and strategic business developments position the company well for sustaining its earnings momentum into 2025.